Merus Labs International Inc. (Merus), formerly Envoy Capital Group Inc., is a specialty pharmaceutical company. The Company is engaged in the acquisition and licensing of branded prescription pharmaceutical products. It has products in the area of urology/women's health, anti-infective, and wound care. Its products include Factive, Emselex/Enable, Vancocin and Collacare and Collexa. On January 6, 2012, the Company acquired 51% of Orbis Pharma Inc. On March 7, 2012, the Company completed the acquisition of the North American product rights for FACTIVE (Gemifloxacin Mesylate) tablets from Cornerstone Therapeutics Inc. On July 11, 2012, the Company acquired the Canadian and European rights (excluding France, Spain and Italy) to manufacture, market, and sell the branded prescription medicine product Emselex/Enablex (darifenacin) extended release tablets.